Baricitinib — Drug Intelligence | 31 EU Trials

Filter these 31 trials by condition, phase, country and more.

Open in Search →

31 Registered trials

15 Recruiting

12 Completed trials

17 Sponsors

24 Countries

Phase III

Phase II

Phase IV

Phase III: 14 Phase II/III: 2 Phase II: 8 Phase III/IV: 1 Phase IV: 6

Oversight events:

1 serious breach 1 temporary halt 1 unexpected event 1 corrective measure across 3 trials

View oversight register →

Indications tested

Polymyalgia rheumatica 2 Dermatomyositis 1 Rheumatoid arthritis 1 Juvenile idiopathic arthritis 1

Sponsors using this IMP

Eli Lilly & Co. 9 Assistance Publique Hopitaux De Paris 5 Centre Hospitalier Universitaire De Nantes 3 Centre Hospitalier Regional Et Universitaire De Brest 1 Centre Hospitalier Universitaire De Bordeaux 1 Centre Hospitalier Universitaire Rouen 1 Fundacion Fls De Lucha Contra El Sida Las Enfermedades Infecciosas Y La Promocion De La Salud Y La Ciencia 1 Hospital Universitario La Paz 1 IRCCS Istituto Giannina Gaslini 1 Les Hopitaux Universitaires De Strasbourg 1 Medical University Of Vienna 1 Oslo University Hospital HF 1

All trials

31 total

Baricitinib for treating hospital-acquired pneumonia in critically ill patients with a proinflammatory phenotype, an international phase II … Not authorised

2023-503480-42-00 Phase II/III 4 countries Centre Hospitalier Universitaire De Nantes
Research into existing medicines to reduce aging, pain, and inflammation in osteoarthritis. Not authorised

2025-524885-12-00 Phase II 1 country Radboud universitair medisch centrum Stichting
BOOSTERS - BiOlogics in FOlliculitis decalvanS : an adaptaTivE tRial reSearch Pending

2024-514848-88-00 Phase II 1 country Assistance Publique Hopitaux De Paris
PALETTE - Trial for personalisation of sepsis treatment in children and adults Pending

2025-521371-31-00 Phase II 1 country Assistance Publique Hopitaux De Paris
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRES… Recruiting

2025-522170-36-00 Phase III 12 countries Eli Lilly & Co.
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults (BARICADE-DELAY) Recruiting

2025-521797-34-00 Phase III 11 countries Eli Lilly & Co.
Toward personalized medicine to guide drug withdrawal in children with juvenile idiopathic arthritis in clinical remission: a randomized cli… Recruiting

2024-514732-24-00 Phase IV 7 countries IRCCS Istituto Giannina Gaslini
Characterization of the immune response in immunosuppressed patients with rheumatic diseases, including to the recombinant zoster vaccine Recruiting

2024-518190-34-00 Phase IV 1 country Centre Hospitalier Universitaire De Toulouse
Justification AnD evaluation, in pOlymyalgia RhEumatica, of BARIcitinib versus placebo (JADORE-BARI study) Recruiting

2024-518385-26-01 Phase III 1 country Centre Hospitalier Regional Et Universitaire De Brest
REDO-JAK: Dose REDuction Of JAnus Kinase inhibitors in patients with inflammatory rheumatic diseases Recruiting

2025-520757-36-00 Phase IV 1 country Sint Maartenskliniek Stichting
JAK inhibitor dose TAPering strategy study in low disease activity rheumatoid arthritis patients. Recruiting

2023-509788-25-00 Phase IV 1 country Centre Hospitalier Universitaire De Toulouse
Combination of baricitinib and anti-TNF in rheumatoid arthritis Recruiting

2024-511442-39-00 Phase III 1 country Centre Hospitalier Universitaire De Bordeaux
“The BAPTIST study” Baricitinib in calcium pyrophosphAte dePosiTion dIseaSe Trial – a proof of concept phase II clinical trial . Recruiting

2024-511864-95-00 Phase II 1 country Ospedale Galeazzi S.p.A.
Optimization of atopic dermatitis treatment that requires second-line systemic therapy through multiomic predictive models of treatment resp… Recruiting

2023-506165-62-00 Phase IV 1 country Hospital Universitario La Paz
Baricitinib in patients with relapsing or naïve dermatomyositis (BIRD) Recruiting

2024-511899-32-00 Phase II/III 1 country Assistance Publique Hopitaux De Paris
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With sJIA Recruiting

2023-507883-38-00 Phase III 7 countries Eli Lilly & Co.
A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Ante… Recruiting

2023-505811-18-00 Phase III 3 countries Eli Lilly & Co.
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JUVE-X) Recruiting

2023-506131-15-00 Phase III 9 countries Eli Lilly & Co.
RANDOMIZED CONTROLLED CLINICAL TRIAL EVALUATING METHOTREXATE OR LEFLUNOMIDE + TARGETED THERAPY VERSUS METHOTREXATE OR LEFLUNOMIDE + SULFASAL… Recruiting

2024-516704-41-00 Phase III/IV 1 country Les Hopitaux Universitaires De Strasbourg
Safety and Impact of Baricitinib on Cell Surivival Pathways, HIV-1 Reservoir and Inflamation in People With HIV-1 Ended

2024-520159-26-00 Phase II 1 country Fundacion Fls De Lucha Contra El Sida Las Enfermedades Infecciosas Y La Promocio…
JAK1 inhibitor treatment of inflammatory liver adenomas Ended

2023-505278-13-00 Phase II 1 country Assistance Publique Hopitaux De Paris
Inhibition of JAK enzymes in early stage joint inflammation Ended

2024-514026-23-00 Phase II 1 country Universitaetsklinikum Erlangen AöR
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata (BRAVE-AA-PEDS) Ended

2022-502700-78-00 Phase III 5 countries Eli Lilly & Co.
Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) Ended

2023-507889-89-00 Phase III 13 countries Universitair Medisch Centrum Utrecht

Showing 1–24 of 31 trials

← All drugs A–Z